Ultragenyx Faces Two Gene-Therapy Decision Dates 27 Days Apart, One a Re-Run of a Manufacturing Rejection

by Sofia Lindqvist · August 16, 2026

Markets Writer, The SmallCap Signal

Ultragenyx Pharmaceutical (Nasdaq: RARE) has spent a decade building a commercial rare-disease business around four marketed products. Over the next five weeks it finds out whether it becomes a gene-therapy company as well. The Food and Drug Administration has set target action dates for two of the company's adeno-associated virus gene therapies just 27 days apart, and one of them is a second pass at an application the agency turned down in 2025 on manufacturing grounds.

The first is DTX401, also known as pariglasgene brecaparvovec, an AAV8 gene therapy for glycogen storage disease type Ia. Ultragenyx announced on February 23, 2026 that the FDA had accepted the biologics license application and granted Priority Review, with a target action date of August 23, 2026. The second is UX111, an AAV gene therapy for mucopolysaccharidosis type IIIA, better known as Sanfilippo syndrome type A. The company said on April 2, 2026 that the FDA had accepted its resubmitted application, with a target action date of September 19, 2026. Both dates were reaffirmed in the company's second-quarter release on August 4.

A caveat that matters more than it sounds: August 23, 2026 is a Sunday and September 19, 2026 is a Saturday. Prescription Drug User Fee Act goal dates are internal performance targets the agency sets for itself, not appointments. Action can arrive ahead of the date, on an adjacent business day, or later than the goal entirely. Anyone reading a headline that says the FDA will decide on a weekend is reading a calendar, not a schedule.

On DTX401, the case Ultragenyx has put in front of the agency rests on the Phase 3 GlucoGene program. Per the company's February BLA acceptance release, the submission covered 52 treated patients with up to six years of follow-up. Glycogen storage disease type Ia is managed today largely through relentless dietary control, and the endpoints the company has emphasised reflect that: reductions in the quantity and frequency of daily cornstarch intake, maintenance of low hypoglycemia levels, improved euglycemia, better fasting tolerance, and patient-reported quality-of-life improvements measured on the Patient Global Impression of Change scale. Eric Crombez, the company's chief medical officer, said in that release: "Current dietary approaches to managing GSDIa place an extraordinary burden on individuals and families while still leaving patients with significant medical needs, including the risk of potentially life-threatening episodes of acute hypoglycemia and accumulation of long-term complications over their lifetime. If approved, DTX401 would be the first treatment to address the disease at its root cause."

UX111 is the more complicated file, and the reason is worth stating precisely because it is easy to get backwards. The FDA issued a Complete Response Letter on July 11, 2025. According to Ultragenyx's own description of that letter, the deficiencies were confined to chemistry, manufacturing and controls, arising from observations at recently completed manufacturing facility inspections. The company described them as "readily addressable, related to facilities and processes, and ... not directly related to the quality of the product." It further stated that the letter did not note any review issues related to the clinical data package nor clinical inspections, and that the agency characterised the neurodevelopmental outcome data provided to date as robust, with biomarker data providing additional supportive evidence.

That distinction is the whole story on UX111. This is not a rejection that questioned whether the therapy works. It is a rejection that questioned how it is made and where. Framing the September date as an efficacy referendum would misread the record. The open question is a manufacturing and process review, and those are resolved through documentation, remediation and, where applicable, facility inspection, not through more patient data.

Chief executive Emil Kakkis said at the time of the letter: "Our goal is to get UX111 to patients as quickly as possible knowing how critical this first therapy is to the Sanfilippo community. We have been diligently responding to the recent CMC observations and our priority is to resolve them so that we can resubmit the BLA as soon as possible. We believe the CMC observations are readily addressable and many have already been addressed. While the CRL will delay the potential approval of UX111 to 2026, we are working with urgency to respond and resubmit." On the April acceptance of the resubmission, Kakkis said: "The FDA's acceptance of the BLA for UX111 brings us closer to the possibility of a first-ever therapy for Sanfilippo syndrome Type A—a milestone that we recognize cannot come soon enough for families facing this devastating diagnosis. We appreciate the FDA's prompt acceptance of the resubmission and look forward to working with the Agency throughout its review in order to bring this treatment option to the Sanfilippo syndrome community as quickly as possible." The company is pursuing accelerated approval for the program.

The clinical package behind UX111 comes from the Transpher A study. In longer-term data released February 3, 2026, Ultragenyx reported a median reduction in cerebrospinal fluid heparan sulfate of 63.98 percent, with a p-value below 0.001, in an efficacy set of 27 patients drawn from a safety set of 33, with follow-up extending up to 8.5 years and a median of 4.8 years for safety. In a cohort of 17 patients treated at age two or younger or with a cognitive developmental quotient of 60 or above, the company reported a 23.2-point advantage on the Bayley-III cognitive scale against natural history across ages 24 to 60 months, with p below 0.0001, alongside gains of 8.1 points in receptive communication (p=0.0076), 11.1 points in expressive communication (p=0.0008) and 9.0 points in fine motor (p=0.0026). Gross motor showed a 3.9-point gain that did not reach conventional significance, at a p-value of 0.070.

There is a thread connecting the two applications that is easy to miss when they are treated as separate catalysts. Manufacturing is common to both. Ultragenyx said DTX401 is planned for manufacture at its own facility in Bedford, Massachusetts. For UX111, the company has identified Andelyn Biosciences in Columbus, Ohio and the Bedford facility. A company whose one prior gene-therapy rejection was CMC-only is now asking the agency to sign off on two AAV products within a month of each other, with the Bedford site named in both filings. How far the overlap runs is not public: the July 2025 letter release named neither Bedford nor Andelyn, so which facility generated the inspection observations, and whether it is a site DTX401 also relies on, is not disclosed. Whether the agency's comfort with that base has changed since July 2025 is the variable that runs through both dates, and it is not one outside observers can score from public documents.

The balance sheet gives that timeline its stakes. Ultragenyx reported cash, cash equivalents and marketable securities of $436 million as of June 30, 2026. That is the last reported balance-sheet figure, and it pre-dates the third quarter; a review of the company's news flow since the August 4 results release surfaced no equity offering, at-the-market sale, convertible note or debt raise, but the $436 million should be read with its as-of date attached. The August 4 results release is the most recent item in the company's press-release archive, and the most recent underwritten public offering of common stock listed there closed in October 2023.

Unlike most companies waiting on gene-therapy decisions, Ultragenyx is not pre-revenue. Second-quarter 2026 total revenue was $214 million on a GAAP basis, up from $167 million a year earlier, comprising Crysvita at $156 million, Dojolvi at $27 million, Evkeeza at $21 million and Mepsevii at $10 million. The GAAP net loss for the quarter was $92 million, or $(0.90) per share on a basic and diluted basis, against a six-month GAAP net loss of $277 million, or $(2.73) per share. The company did not present non-GAAP measures in the release.

Full-year 2026 guidance was reaffirmed at $730 million to $760 million of total revenue, explicitly excluding any contribution from potential new product launches, with Crysvita guided to $500 million to $520 million and Dojolvi to $100 million to $110 million. The company said it remains on a path to profitability in 2027. That guidance construction is the point: the commercial base is underwritten without either gene therapy, so the August and September dates are additive to a plan rather than load-bearing for it. What they do change is how much of the existing cash the company needs to hold back, since a launch consumes capital before it returns any.

The shares ended the regular session on Friday, August 14 at $26.49, a close stamped 4:00 p.m. Eastern that day in market data compiled by MarketBeat, giving a market capitalisation of roughly $2.61 billion against a 52-week range of $18.29 to $39.89 and about 98.6 million shares outstanding. At that size Ultragenyx sits at the boundary between small and mid cap; it is not a micro-cap, and treating it as a typical small-cap binary event company understates both its revenue base and its float. Nothing here is a view on the shares, and nothing about a regulatory calendar tells an investor what the agency will conclude.

One practical warning for anyone tracking these dates through a screener. Third-party PDUFA calendars go stale, and a date that has moved can sit uncorrected for months. Savara (Nasdaq: SVRA) and molgramostim are the live example: the widely circulated August 22, 2026 action date no longer applies. Savara announced on April 15, 2026 that the FDA had determined the company's responses to recent agency information requests constituted a major amendment to the application, extending the review by three months to November 22, 2026, with the company noting the agency had raised no safety, efficacy or manufacturing concerns. Savara is not an August catalyst, and the fact that it still appears as one is a reason to source every date from a company filing or release rather than an aggregator. For Ultragenyx, the dates to check against primary documents are August 23 and September 19 — and to check as targets, not appointments.